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The 4th Global Forum on TB Vaccines, convened in Shanghai, China, from 21 e 24 April 2015, brought
together a wide and diverse community involved in tuberculosis vaccine research and development to
discuss the current status of, and future directions for this critical effort. This paper summarizes the
sessions on Low-Dose NHP Challenge Models, Novel Approaches to Animal Models for TB Vaccine R&D,
Novel Antigen Delivery Strategies, and Next Generation TB Vaccines and Vaccine Concepts. Summaries of
all sessions from the 4th Global Forum are compiled in a special supplement of Tuberculosis. [August
2016, Vol 99, Supp S1, S1eS30].
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Preclinical investigations, particularly challenge studies in small
animal species such as mice and guinea pigs, often ultimately
leading to challenge studies in non-human primates (NHPs),
represent a critical step in the development of many vaccines. This
is particularly true when developing vaccines for tuberculosis (TB)
due to the lack in our understanding of the correlates of immu-
nological protection against either TB disease, or infection with
Mycobacterium tuberculosis (Mtb), which might otherwise guide
the vaccine development process. Despite the importance of pre-
clinical animal challenge models, however, a preclinical vaccine
animal model known to reliably predict the potential for a vaccine
to protect against TB in humans does not yet exist.
An additional challenge to TB vaccine development is the need
to diversify the pipeline of vaccine candidates and vaccine strate-
gies. Three vaccine delivery platforms e whole cell vaccines,
adjuvanted protein subunits and subunit vaccines expressed in
viral vectors e comprise the current clinical pipeline. All vaccines
currently in clinical trials were selected based on their ability to
induce classical TH-1 biased CD4þ T-cell and, to a lesser extent,
CD8þ T-cell responses. Generating a broader diversity of immunelevard, Rockville, MD, 20850,
Ltd. This is an open access article uresponses is now considered a priority in assembling the compo-
nents of a successful TB vaccine strategy.
2. Existing and novel approaches to preclinical assessment of
new TB vaccines
Historically, with the NHP TB platforms, relevant biological ef-
fects of vaccine candidates (e.g., reduced pathology, improved
clinical signs, or reduction in bacterial burden) have been assessed
following high doses of challenge organisms, ranging from hun-
dreds to more than a thousand colony forming units (CFUs) of
virulent Mtb strains often delivered directly into the pulmonary
space via bronchoscopic administration. Recently, the ﬁeld has
recognized that these supraphysiological challenge doses and the
unnatural route of exposure may be misleading when assessing
vaccine effects. Accordingly, recent efforts have focused on devel-
oping the NHP challenge model to better approximate the condi-
tions of natural human Mtb infection.
Dr. Philana Ling Lin (University of Pittsburgh, USA) provided a
comprehensive overview of cutting edge practices in NHP
studies, focusing upon the application of modern technologies,
such as positron emission tomography/computerized tomogra-
phy (PET/CT) imaging and methods to assess the establishment
of Mtb infection and subsequent disease progression following
low-dose Mtb exposure. She also addressed the potential of using
imaging to predict outcome of TB vaccines as well as the chal-
lenges to how this may translate to human infection. Unlikender the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and die, generally within four months of a pulmonary Mtb
challenge, 50% of cynomolgous macaques (CM) infected via
bronchoscopic instillation with low dose (~25 CFU) Erdman
strain Mtb develop asymptomatic, latent TB infection (LTBI),
while the other 50% progress rapidly to active TB disease. This
represents a reasonable approximation of Mtb infection in
humans, where 90% of infected persons develop asymptomatic,
latent infection while the other 10% develop active TB disease at
some point in their lives. Despite normal-appearing chest X-rays,
necropsies of these animals reveal a full spectrum of granuloma
types, including caseous, non-necrotizing and ﬁbrotic granu-
lomas. In her experiments, PET/CT images were obtained at
weeks 3, 6 and 8 after challenge and monthly thereafter. As early
as three weeks after infection, animals that would later develop
LTBI had fewer granulomas detected by PET/CT compared to
active TB animals. On an individual granuloma level, granulomas
from animals that would develop active disease had greater
ﬂuorodeoxyglucose (FDG) avidity by 6 weeks post-infection
(termed “PET-hot” lesions) compared to those that would be
latent. At 6 weeks, when pulmonary PET-hot lesions represent
the development of secondary granulomas, CMs that developed
LTBI demonstrated far fewer lesions compared to progressors,
likely reﬂecting development of an adaptive immune response
more capable of controlling Mtb infection as compared to CMs
that progressed to disease [1]. Data so far suggest that greater
pulmonary inﬂammation in the early stages of Mtb infection may
indicate a poorer chance of controlling the infection at later
stages. Increased lung inﬂammation early during infection was
associated with increased mycobacterial burden detected at
necropsy, 21 weeks after challenge. A reduction in the number of
PET-hot lesions that develop between 3 and 6 weeks could
represent an early indicator of vaccine effect, as, according to Lin,
this is a critical period when a vaccine has an opportunity to
increase the potential for a favorable outcome, such as decreasing
the likelihood of progression to disease, or even preventing the
establishment of Mtb infection. Lin concluded by noting that
expanded utilization and harmonization of this important im-
aging tool would permit a more efﬁcient and accurate assess-
ment of CMs undergoing Mtb challenge following administration
with a vaccine candidate and thereby accelerate and improve
preclinical TB vaccine development.
Pia Steigler (University of Otago, New Zealand), addressed the
question whether BCG-induced protection against TB is medi-
ated by memory T-cells. The current dogma implies that TB
vaccine-mediated protection largely is based on memory CD4þ
T-cells. Hence, the potential for vaccines to provide protective
efﬁcacy in (pre)clinical trials is evaluated by their ability to
induce antigen-speciﬁc CD4þ T-cell responses. However, mouse
models illustrating the importance of memory CD4þ T-cells may
be ﬂawed [2].
Steigler used a novel murine memory T-cell depletion model
to investigate the role of BCG-induced memory CD4þ and CD8þ
T-cells in protection against mycobacterial challenge. BCG-
vaccinated mice lacking memory CD4þ, CD8þ or both T-cell
subsets were protected against mycobacterial challenge
compared to unvaccinated mice. Her ﬁndings suggest that BCG-
mediated protection can be independent of memory CD4þ and
CD8þ T-cells.
Dr. Frank Verreck (Biomedical Primate Research Centre, the
Netherlands) assessed both the variable response to Mtb challenge
seen in different RM populations, and the effects of mucosal ascompared to standard intradermal BCG administration in RM
challenge models. Verreck noted that Indian RMs are more sus-
ceptible to TB disease than Chinese RMs following Mtb challenge.
The efﬁcacy of BCG-induced protection varies, but is independent of
genotype. He cautioned that challenge experiments assessing
vaccine-induced protection in NHPs needed to be assessed in the
context of the natural susceptibility of each NHP genotype or cohort
to Mtb infection. Additionally, Verreck noted that a mucosal BCG
vaccination route (intra-nasal administration in his laboratory),
demonstrates protective effects in RMs where standard intrader-
mal BCG administration fails to protect, suggesting that adminis-
tering TB vaccines via the respiratory mucosa should be explored to
a greater extent.
Dr. Sally Sharpe (Public Health England, UK) updated her efforts
to develop an ultra-low dose aerosol NHP challenge model. As
discussed above, most NHP challenge models have used an Mtb
dose that is far greater than the 1e5 CFU representing natural
human Mtb exposure. Sharpe and colleagues have developed an
ultra-low dose challenge model in RMs and CMs in which
approximately 25 CFUs are presented via aerosol with an estimated
retained dose of 3e4 CFUs, inducing as few as ﬁve primary lesions
in the lung. CT scans collected 3 weeks after aerosol exposure
demonstrated that the number of lesions was similarly low and
consistent across species (range: 1e10) withmedians of six nodules
for RMs and four nodules in CMs. Using this ultra-low dose, Erdman
strain aerosol Mtb challenge, they found that RMs developed slow
but progressive TB disease. In contrast, CMs provedmore capable of
controlling Mtb infectionwithout inevitable progression to disease,
as also found by Lin and colleagues (discussed above). Sharpe
concluded by noting the importance of further developing this
ultra-low challenge model given its close approximation to natural
human Mtb exposure and the potential for providing preclinical TB
vaccine efﬁcacy assessments more reﬂective of the clinical outcome
in humans [3].
Dr. Angelo Izzo (Colorado State University, USA) described the
potential utility of the guinea pig (GP) Mtb challenge model
when assessing candidate TB vaccines. The Hartley strain of GP is
highly susceptible to TB, and BCG vaccination prolongs survival
of Hartley GPs following Mtb challenge. Izzo described three
general categories of disease progression manifest in Mtb-
infected GPs: acute, progressive and chronic. Izzo and col-
leagues studied the relationship between selected immunolog-
ical and non-immunological factors and the extent of post-Mtb
challenge survival. In both unvaccinated GP and BCG vaccinated
GP groups, some survived nearly two years post infection, sug-
gesting that survivability post-Mtb challenge was not necessarily
conferred by BCG vaccination but was likely to have resulted
from immune responses innate to particular GPs. He noted that a
greater elucidation of the natural history of Mtb infection in GPs
is needed to permit a better understanding of the functional
impact of vaccination on altering the natural course of Mtb
infection in GPs.
3. Novel Antigen Delivery Strategies
The development of new viral vectors for Mtb vaccines,
including Sendai virus, lentivirus, parainﬂuenza virus 2, and inﬂu-
enza virus, provided the focus for a breakout session on Novel
Antigen Delivery Strategies. Viral vector vaccines generally consist
of a live, attenuated virus genetically engineered to deliver a
transgene encoding a foreign antigen(s) from an unrelated organ-
ism. Similar to whole cell vaccines, viral vectors have the potential
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recognition receptors (e.g., Toll-like receptors) and drive the pro-
duction of antigen in vivo.
Dr. Zhidong Hu (Shanghai Public Health Clinical Center, Fudan
University, China) described the use of a Sendai virus (SeV)
vectored TB vaccine developed as a replication-deﬁcient carrier for
Ag85A and Ag85B antigens (SeV85AB). According to Dr. Hu, a single
intranasal administration in mice induced potent, antigen-speciﬁc
T-cell responses in the draining lymph nodes and lung, to the
same extent as BCG. Following SeV85AB vaccination, they observed
a greater reduction in Mtb load and an enhanced pulmonary CD8þ
T-cell response as compared to Mtb challenge in BCG-vaccinated
mice. Hu suggested that the SeV85AB vaccine may represent a
potent booster to BCG, given that the SeV85AB vaccine demon-
strated a 0.5 log improvement in protection in a mouse challenge
when used as a boost to BCG, as compared to a degree of protection
similar to that of BCG when used as a stand-alone vaccine. Addi-
tionally, by inducing high levels of local and systemic CD8þ T-cell
responses, SeV85ABmay represent a promising therapeutic vaccine
candidate for use in persons with active TB disease. When ques-
tioned about the safety of an SeV-vectored construct for human
use, Hu noted that demonstration of safety would be a particularly
important component of any effort to move this construct forward
in clinical trials.
Dr. Mohamad F Jamiluddin (Theravectys, France) described a
therapeutic vaccine using optimized lentiviral vectors (LVs)
partially derived fromHIV for potential use in treating persons with
multidrug-resistant TB (MDR-TB). A speciﬁc modiﬁcation to the
virus provided the LV construct with a unique ability to express the
transgene efﬁciently in non-dividing cells, including dendritic cells
[4]. The packaging capacity of the LV system is relatively large,
allowing up to 15 Kb insert to be included and therefore offering the
advantage of generating a component LV vector vaccine containing
genes expressing antigens found during different stages of Mtb
infection. Four different LV constructs were designed, each
encompassing classical, latent and resuscitation antigens fromMtb.
These constructs will be further evaluated in mouse protection
studies.
Prof. Dr. Yasuhiro Yasutomi (National Institutes of Biomedical
Innovation, Health and Nutrition, Japan) presented the develop-
ment of a recombinant human parainﬂuenza type 2 virus (rHPIV2)
vectored intranasal vaccine against Mtb infection. The deletion of
the M gene results in a single cycle infection. Further attenuation
was attained by eliminating selected HPIV genes that are involved
in immune evasion. An HPIV2 vector expressing Ag85B was
effective in inducing high numbers of IFN-g secreting cells in
lymph nodes and locally in bronchoalveolar lavage (BAL) cells
after intranasal administration in mice. After Mtb challenge, an-
tigen speciﬁc systemic and mucosal responses were detected that
were stronger than those observed in subcutaneous BCG immu-
nized mice. The mechanism is yet to be understood since mice are
not susceptible to HPIV2 infection. Additionally, the HPIV2 viral
vectors offer potent adjuvant activity by activation of innate im-
mune receptors through viral ssRNA. The rHPIV2 vectored vaccine
was shown to be a single cycle vector, i.e., one that does not
demonstrate multiple-stage growth in cells, and may therefore
considered to be safer than vectors capable of extended replica-
tion. This was only conﬁrmed in M-gene transfected cell lines,
however, and questions regarding in vivo safety remain to be
addressed.
Dr. Marina Stukova (Research Institute of Inﬂuenza, Russia)
presented a phase 1 trial with an inﬂuenza vector-based TB vaccine,expressing Ag85A and ESAT-6 (TB/FLU-04L). Dr. Stukova noted that
live, inﬂuenza virus, attenuated through truncation of the viral NS1
protein, has a benign safety proﬁle in humans and is highly
immunogenic, making it an attractive candidate to serve as a vac-
cine vector. A genetically stable, replication-deﬁcient inﬂuenza viral
vector harboring ESAT6-Ag85A was generated which showed
increased antigen-speciﬁc IFN-g responses inmice and cynomolgus
monkeys. When tested in a clinical phase 1 study as a nasal spray,
the vaccine was well tolerated with no serious adverse events or
viral shedding reported. Local nasal cytokine production (IL-1b,
TNFa and IL2) was determined as early immune responses to
vaccination. Both antigen-speciﬁc memory CD4þ and CD8þ T-cell
responses were observed after two vaccinations. T-cell responses to
Ag85A peaked at 21 days and subsequently decreased, while re-
sponses to ESAT-6 peaked at 21 days but were sustained
throughout the course of study. No antibody response against
inﬂuenza vector was noted.
Prof. Warwick Britton (University of Sydney, Australia) pre-
sented preliminary data from studies of mice immunized intra-
nasally with a recombinant inﬂuenza A virus-based vaccine
(rIAV). The PR8 H1N1 and X31 H3N2 strains of IAV were genet-
ically modiﬁed to express speciﬁc mycobacterial antigens,
including Ag85B and TB10.4. These constructs induced strong,
antigen-speciﬁc CD4þ T-cell responses in the lung that persisted
over 12 weeks post infection. A single administration of the PR8
virus expressing one Mtb-speciﬁc CD4þ T-cell epitope from
Ag85B, but not an Mtb-speciﬁc CD8þ T-cell epitope from TB10.4,
was sufﬁcient to confer protection in the lungs against Mtb
challenge, with efﬁcacy similar to that of BCG. Heterologous virus
boosting resulted in signiﬁcantly higher numbers of IFN-g pro-
ducing CD4þ T-cells compared to immunization with single vi-
ruses. Sequential immunization with PR8-p25 and X31-p25
strongly boosted T-cell responses after BCG prime. Prior BCG
immunization boosted with PR8-p25 and X31-p25 enhanced
these pulmonary CD4þ T-cell responses against Mtb even more
efﬁciently. Therefore rIAV vectors can stimulate strong protective
CD4þ T cell responses against Mtb [5].
4. Next generation TB vaccines and new vaccine concepts
Dr. Olivier Neyrolles, (IPBS, CNRS-University of Toulouse,
France) introduced the objectives of a new TB vaccine research
consortium, TBVAC2020. The consortium is supported by Horizon
2020, the European Union's current Framework Programme for
Research and Innovation, and dedicates a major part of the work
program to discovery of new antigens, delivery systems, immu-
nization strategies, and novel live vaccines. TBVAC2020 is coor-
dinated through the TuBerculosis Vaccine Initiative (TBVI) and
works with the 40 consortium members of TBVAC2020. The main
aim of this program is to broaden and deepen the diversity of the
preclinical vaccine pipeline. The consortium operates a portfolio
management approach built around internationally agreed
gating criteria for product development in a series of well-
deﬁned animal models.
TBVAC2020 will be focused on the following areas: diversity of
antigens & delivery systems; diversity of preclinical models; head-
to-head testing in animal models & preclinical development; clin-
ical development; diversity of biomarkers; and portfolio
management.
TBVAC2020 will attempt to discover novel antigens and epi-
topes using innovative technologies, explore novel stage-speciﬁc
antigens using candidate-based and genome-wide expression
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patient-derived antibodies and undertake Mtb mutant library
screening, discover and exploit novel lipid and glycoconjugate an-
tigens in vitro and in vivo using innovative tools (e.g. recombinant
CD1b, CD1b-Tg mice), and evaluate viral vector-based liposomes
and nanoparticle-based technologies as vaccine candidates. To
select better candidates, they will use a portfolio management
committee (PMC); preclinical models that resemble infection in
humans; independent head-to-head animal testing; and indepen-
dent Phase 1 clinical testing.
Dr. Sarah Marcus (University of WisconsineMadison, USA)
presented ongoing work to develop live, attenuated Mtb-based
vaccines and assess the potential of these vaccines to provide su-
perior protection against TB as compared to BCG vaccine given their
derivation from pathogenic Mtb and potentially prolonged persis-
tence in the host compared to BCG [6]. She described two attenu-
ated Mtb mutants, involving the deletions DmosR and DechA7. The
mosR and ech7 gene regions are necessary for virulence; the MosR
region includes 163 negatively regulated genes [7]. Both strains
were tested as vaccines in C57BL/6mice compared to BCG and a PBS
control, injecting 106 CFU of the vaccine strains subcutaneously 8
weeks prior to aerosol challenge with ~40 CFU of an Mtb Beijing
strain. Both vaccine strains persisted up to 16 weeks in the spleen
and lungs of vaccinated mice. BCG, in contrast, was not detected
after administration. The bacterial burden data showed nearly a log
reduction in the lungs of either DmosR or DechA7 vaccinated mice
compared to BCG vaccinated mice, and a 2 log reduction in viable
bacterial load compared to PBS control mice at both days 30 and 60
post-challenge. Remarkably, by day 60 post-challenge, no Mtb
colonization was observed in the lungs of DmosR vaccinated mice.
Flow cytometry demonstrated that vaccination with DechA7
primed an Mtb speciﬁc IFN-gamma response from CD4þ T-cells
isolated from the lungs 8 weeks following vaccination, signiﬁcantly
greater than that from BCG vaccinated mice, which showed no
response. Cells from the lungs of DmosR vaccinated mice also
showed an enhanced response. Additionally, ELISA assays at 60
days post challenge demonstrated signiﬁcantly higher Mtb speciﬁc
IFN-gamma production by splenocytes isolated from mice vacci-
nated with DmosR compared to those vaccinated with BCG. These
data suggest that the live attenuated vaccines tested in this study
demonstrated better protection than BCG. Future plans include the
placement of both mosR and echA7 deletions in the same Mtb or-
ganism and subsequent assessment in Mtb challenge experiments.
5. Conclusion
Efforts to develop better animal challenge models of TB infec-
tion are ongoing and represent a critically important effort in
accelerating TB vaccine development. Developing a better under-
standing of the implications of post-vaccine Mtb challenge in small
animal models such as mice and guinea pigs, and applying new
imaging technology such as the PET/CT scan and ultra low doses
Mtb administration to NHP challenge models, are high priority
strategies that offer more rapid and accurate assessments of po-
tential vaccine efﬁcacy in humans. Additionally, the need to obtain
a broader view of the diversity of immune response induced by TBvaccines via the development of novel vaccine delivery strategies,
including viral vector platforms, has been recognized as a high
priority in the ﬁeld and represents an area of intense and promising
activity. The ongoing support for these closely related preclinical
strategies will be critical to ensure that robust and efﬁciently
assessed pipeline array of vaccine concepts are available for future
advancement into clinical testing.
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